Altimmune, Inc. (ALT)
3.155
-0.04
(-1.41%)
USD |
NASDAQ |
Aug 26, 16:00
3.16
0.00 (0.00%)
After-Hours: 20:00
Altimmune Enterprise Value : 332.01M for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 332.01M |
| August 24, 2026 | 314.51M |
| August 21, 2026 | 314.51M |
| August 20, 2026 | 283.40M |
| August 19, 2026 | 316.46M |
| August 18, 2026 | 287.29M |
| August 17, 2026 | 293.12M |
| August 14, 2026 | 281.45M |
| August 13, 2026 | 269.78M |
| August 12, 2026 | 279.51M |
| August 11, 2026 | 293.12M |
| August 10, 2026 | 302.84M |
| August 07, 2026 | 308.68M |
| August 06, 2026 | 295.06M |
| August 05, 2026 | 298.95M |
| August 04, 2026 | 306.73M |
| August 03, 2026 | 293.12M |
| July 31, 2026 | 262.00M |
| July 30, 2026 | 289.23M |
| July 29, 2026 | 277.56M |
| July 28, 2026 | 291.17M |
| July 27, 2026 | 285.34M |
| July 24, 2026 | 248.39M |
| July 23, 2026 | 262.00M |
| July 22, 2026 | 256.17M |
| Date | Value |
|---|---|
| July 21, 2026 | 258.11M |
| July 20, 2026 | 256.17M |
| July 17, 2026 | 267.84M |
| July 16, 2026 | 263.95M |
| July 15, 2026 | 289.23M |
| July 14, 2026 | 279.51M |
| July 13, 2026 | 291.17M |
| July 10, 2026 | 302.84M |
| July 09, 2026 | 316.46M |
| July 08, 2026 | 314.51M |
| July 07, 2026 | 297.01M |
| July 06, 2026 | 308.68M |
| July 02, 2026 | 324.24M |
| July 01, 2026 | 322.29M |
| June 30, 2026 | 300.90M |
| June 29, 2026 | 87.12M |
| June 26, 2026 | 71.49M |
| June 25, 2026 | 78.00M |
| June 24, 2026 | 88.42M |
| June 23, 2026 | 83.21M |
| June 22, 2026 | 85.81M |
| June 18, 2026 | 55.86M |
| June 17, 2026 | 48.05M |
| June 16, 2026 | 45.44M |
| June 15, 2026 | 48.05M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Amgen, Inc. | 282.39B |
| Protalix Biotherapeutics, Inc. | 161.20M |
| Taysha Gene Therapies, Inc. | 1.618B |
| Humacyte, Inc. | 180.92M |
| Liquidia Corp. | 6.179B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -22.82M |
| Total Expenses (Quarterly) | 22.82M |
| EPS Diluted (Quarterly) | -0.1231 |
| Earnings Yield | -25.00% |
| Normalized Earnings Yield | -24.91 |